EUCTR2008-000150-12-SE进行中（未招募）不适用
A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Tolerability of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Infection
Merck Sharp & Dohme (Sweden) AB0 个研究点目标入组 300 人开始时间: 2008年4月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients (men and women 18 to 65 years of age) with chronic compensated genotype 1 HCV infection as defined by 1) positive serology for HCV with HCV RNA levels =4 ×105 IU/mL in peripheral blood at screening (within 60 days prior to the first dose of MK-7009); 2) evidence of chronic HCV infection as assessed by positive serology for HCV or detectable HCV RNA =6 months prior to the first dose of MK-7009; and 3) absence (no medical history or physical findings) of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease.
- •Patient has received and tolerated coadministered peg-IFN (alfa-2a or -2b) and RBV, but failed to respond to at least one prior treatment course of at least 12 weeks duration. Patient's HCV treatment history (i.e., type of therapy and duration of therapy) and response to prior treatment (i.e., tolerability and HCV RNA data) should be available such that one of the following definitions are met: 1-Null Response: <2-log10 IU/mL decline in HCV RNA from the pretreatment baseline to treatment Week 12 (+1 week); 2-Partial Response: =2-log10 IU/mL decline in HCV RNA from the pretreatment baseline to treatment Week 12 (+1 week), with detectable HCV RNA at treatment Week 24; 3-Breakthrough: Detectable HCV RNA during treatment after initially achieving undetectable HCV RNA; 4-Relapse: Detectable HCV RNA after completion of 48 weeks or more of treatment in patients who achieved undetectable HCV RNA and maintained undetectable HCV RNA throughout the remainder of the treatment period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient has non-genotype 1 HCV infection, including mixed genotype and has evidence or history of chronic hepatitis not caused by HCV, including but not limited to non-alcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune hepatitis.
- •Patient was previously unable to complete 12 weeks of peg-IFN- or RBV-containing regimen due to intolerance of peg-IFN or RBV.
- •In the opinion of the investigator, the patient is unlikely to tolerate at least 24 weeks of continuous therapy with peg-IFN and RBV.
研究者
相似试验
进行中（未招募）
不适用
A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Ribavirin in Treatment-Experienced Patients with Chronic Genotype 1 Hepatitis C Virus InfectioChronic hepatitis C infectionMedDRA version: 9.1Level: LLTClassification code 10019751Term: Hepatitis C virusEUCTR2008-000150-12-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
进行中（未招募）
不适用
A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Patients With Chronic Hepatitis C Infection.EUCTR2008-000149-72-DEMerck & Co., Inc.176
进行中（未招募）
1 期
A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Ribavirin in Treatment-Experienced Patients with Chronic Genotype 1 Hepatitis C Virus Infection. - Add-on study of MK-7009 to PEG interferon and Ribavirin.Chronic hepatitis C infectionMedDRA version: 9.1Level: LLTClassification code 10019751Term: Hepatitis C virusEUCTR2008-000150-12-BEMerck Sharp & Dohme (Europe) Inc.160
进行中（未招募）
不适用
A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Ribavirin in Treatment-Experienced Patients with Chronic Genotype 1 Hepatitis C Virus InfectionChronic hepatitis C infectionMedDRA version: 9.1Level: LLTClassification code 10019751Term: Hepatitis C virusEUCTR2008-000150-12-ATMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
已完成
不适用
A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 Hepatitis C Virus Infectio-B182 Chronic viral hepatitis CChronic viral hepatitis CB182PER-090-09MERCK SHARP & DOHME PERU S.R.L.,